Skip Navigation

This Article
Right arrow Print PDF (2031K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Davies, S. M.
Right arrow Articles by Hickson, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, S. M.
Right arrow Articles by Hickson, I. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1989, Vol. 17, No. 4 1337-1351
© 1989


ENZYMOLOGY

Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant

Stella M. Davies, Adrian L. Harris and Ian D. Hickson*

Cancer Research Unit, Department of Clinical Oncology, Medical School, University of Newcastle upon-Tyne NE2 4HH, UK

*To whom correspondence should be addressed

Received January 9, 1989. Accepted January 20, 1989.

Ataxia telangiectesia (AT) cell lines are characterised by their hypersensitivity to ionizing radiation and bleomycin, and their failure to inhibit DNA synthesis after DNA damage. A recent report [Singh et al. (1988) Nucl. Acids Res. 16, 3919–3929] indicated that a reduction in topoisomerase II (topo II) activity was a feature of AT lymphoblast cell lines. We have studied the possible role of DNA topoisomerases in determining the phenotype of an AT fibroblast cell line. AT5BIVA cells are sensitive to the topo II inhibitors etoposide (VP16) and amsacrine (m-AMSA), compared to normal human fibroblasts (MRC5-V1 and VA13). AT5BIVA cells express a 3-fold higher level of topo II protein than MRC5-V1 cells, and 6-fold higher than VA13. This is reflected in elevated topo II activity in AT5BIVA cells. Untransformed AT5BI cells also show elevated topo II activity compared to untransformed normal cells. The extent of overproduction of topo II in AT5BIVA cells is comparable with that seen in a mutant Chinese hamster cell line, ADR-1, which is similarly hypersensitive to both bleomycin and topo II inhibitors. However, ADR-1 cells show neither hypersensitivity to ionizing radiation nor abnormal inhibition of DNA synthesis following DNA damage. Topo II overproduction per se does not appear sufficient to generate an "AT-like" phenotype.

AT5BIVA cells express a reduced level of topoisomerase I (topo I) and are hypersensitive to the topo I inhibitor, camptothecin. ADR-1 cells express a normal level of topo I, indicating that a reduction in the level of topo I is not the inevitable consequence of an elevation in topo II.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Reis, N. Giocanti, C. Hennequin, F. Megnin-Chanet, M. Fernet, R. Filomenko, A. Bettaieb, E. Solary, and V. Favaudon
A role for PKC{zeta} in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin
Mol. Cancer Ther., October 1, 2005; 4(10): 1457 - 1464.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
J. Biol. Chem., April 8, 2005; 280(14): 14349 - 14355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Oguchi, M. Takagi, R. Tsuchida, Y. Taya, E. Ito, K. Isoyama, E. Ishii, L. Zannini, D. Delia, and S. Mizutani
Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement
Blood, May 1, 2003; 101(9): 3622 - 3627.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.